Clinical trials
Carotid Artery Diseases trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 2 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 13 |
| Recruiting | 7 |
| Completed | 5 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shenzhen Wecan Medical Technology Co.,Ltd | 3 |
| First Affiliated Hospital Xi'an Jiaotong University | 2 |
| First Affiliated Hospital of Harbin Medical University | 2 |
| Beijing Friendship Hospital | 1 |
| Beijing Tiantan Hospital | 1 |
| Chinese PLA General Hospital | 1 |
| First Hospital of China Medical University | 1 |
| Fudan University | 1 |
| Guangdong Provincial Hospital of Traditional Chinese Medicine | 1 |
| Jia Liu | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carotid Artery Diseases | 26 |
| Carotid Stenosis | 9 |
| Ischemic Stroke | 4 |
| Atherosclerosis | 3 |
| Cardiovascular Diseases | 2 |
| Hypertension | 2 |
| Hypertrophy, Left Ventricular | 2 |
| Nervous System Diseases | 2 |
| Stroke | 2 |
| Vascular Diseases | 2 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.